Patent classifications
C07C233/87
Compounds for inhibition of α4 β7 integrin
The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.
Compounds for inhibition of α4 β7 integrin
The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.
USP9X inhibitors
The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.
USP9X inhibitors
The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.
Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt. ##STR00001##
Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt. ##STR00001##
USP9X INHIBITORS
The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.
USP9X INHIBITORS
The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.
RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION
A rhein amide derivative and a preparation method and use thereof, and a drug for treating hepatocellular carcinoma (HCC) caused by a specific expression of RECQL4. The rhein amide derivative has a structure shown in any one of formulas I to IV. The rhein amide derivative has a relatively strong inhibitory effect on proliferation of HCC cells SNU-398 with RECQL4 high expression. Development of a novel anti-cancer drug for RECQL4 high expression-caused HCC and clinical personalized treatment of the RECQL4 high expression-caused HCC.
RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION
A rhein amide derivative and a preparation method and use thereof, and a drug for treating hepatocellular carcinoma (HCC) caused by a specific expression of RECQL4. The rhein amide derivative has a structure shown in any one of formulas I to IV. The rhein amide derivative has a relatively strong inhibitory effect on proliferation of HCC cells SNU-398 with RECQL4 high expression. Development of a novel anti-cancer drug for RECQL4 high expression-caused HCC and clinical personalized treatment of the RECQL4 high expression-caused HCC.